Associations between comorbid anxiety,diabetes control,and overall medical burden in patients with serious mental illness and diabetes *

Abstract

Objective

While previous work has demonstrated elevation of both comorbid anxiety disorders and diabetes mellitus type II in individuals with serious mental illness, little is known regarding the impact of comorbid anxiety on diabetes mellitus type II outcomes in serious mental illness populations. We analyzed baseline data from patients with serious mental illness and diabetes mellitus type II to examine relationships between comorbid anxiety, glucose control as measured by hemoglobin A1c score, and overall illness burden.

Methods

Using baseline data from an ongoing prospective treatment study involving 157 individuals with serious mental illness and diabetes mellitus type II, we compared individuals with and without a comorbid anxiety disorder and compared hemoglobin A1c levels between these groups to assess the relationship between anxiety and management of diabetes mellitus type II. We conducted a similar analysis using cumulative number of anxiety diagnoses as a proxy for anxiety load. Finally, we searched for associations between anxiety and overall medical illness burden as measured by Charlson score.

Results

Anxiety disorders were seen in 33.1% (N = 52) of individuals with serious mental illness and diabetes mellitus type II and were associated with increased severity of depressive symptoms and decreased function. Hemoglobin A1c levels were not significantly different in those with or without anxiety, and having multiple anxiety disorders was not associated with differences in diabetes mellitus type II control. However, depressive symptoms were significantly associated with higher hemoglobin A1c levels. Neither comorbid anxiety nor anxiety load was significantly associated with overall medical burden.

Conclusion

One in three people with serious mental illness and diabetes mellitus type II had anxiety. Depressive symptoms were significantly associated with Hb1Ac levels while anxiety symptoms had no relation to hemoglobin A1c; this is consistent with previously published work. More studies are needed to better understand the relationship between depression, anxiety, and health management in people with serious mental illness and diabetes mellitus type II.

Keywords

Serious mental illness schizophrenia bipolar disorder anxiety diabetes mellitus comorbidity

Get full access to this article

View all access options for this article.

References

Kessler

. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617–627.

Braga

R.J

. Anxiety disorders in outpatients with schizophrenia: prevalence and impact on the subjective quality of life. J Psychiatr Res 2005; 39: 409–414.

Achim

. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull 2011; 37: 811–821.

Buckley

. Psychiatric comorbidities and schizophrenia. Schizophr Bull 2009; 35: 383–402.

Cosoff

Hafner

. The prevalence of comorbid anxiety in schizophrenia, schizoaffective disorder and bipolar disorder. Aust NZ J Psychiatry 1998; 32: 67–72.

Keller

. Prevalence and impact of comorbid anxiety and bipolar disorder. J Clin Psychiatry 2005; 67: 5–7.

Kessler

The 12-month prevalence and correlates of serious mental illness (SMI). In: Manderscheid

Sonnenschein

(eds). Mental health, United States, Rockville, MD: US Department of Health and Human Services, 1996, pp. 5600.

van Winkel

. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008; 10: 342–348.

Schoepf

. Type-2 diabetes mellitus in schizophrenia: increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up. Eur Psychiatry 2012; 27: 33–42.

10.

Regenold

. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002; 70: 19–26.

11.

Gomes

. Cardiovascular risk factors in outpatients with bipolar disorder: a report from the Brazilian Research Network in Bipolar Disorder. Rev Bras Psiquiatr 2013; 35: 126–130.

12.

Brown

Mitchell

. Predictors of death from natural causes in schizophrenia: 10-year follow-up of a community cohort. Soc Psychiatry Psychiatr Epidemiol 2012; 47: 843–847.

13.

Mitchell

Dinan

. Schizophrenia: a multisystem disease? J Psychopharmacol 2010; 24(4 Suppl): 5–7.

14.

Mitchell

Malone

. Physical health and schizophrenia. Curr Opin Psychiatry 2006; 19: 432–437.

15.

Mitchell

. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders – a systematic review and meta-analysis. Schizophr Bull 2013; 39: 306–318.

16.

Mitchell

. Clustering of schizophrenia with other comorbidities – what can we learn? Schizophr Bull 2009; 35: 282–283.

17.

Vancampfort

. A meta-analysis of cardio-metabolic abnormalities in drug naive, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 2013; 12: 240–250.

18.

Guo

. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case-control study. J Clin Psychiatry 2006; 67: 1055–1061.

19.

Guo

. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study. Pharmacotherapy 2007; 27: 27–35.

20.

Erickson

. New-onset treatment-dependent diabetes mellitus and hyperlipidemia associated with atypical antipsychotic use in older adults without schizophrenia or bipolar disorder. J Am Geriatr Soc 2012; 60: 474–479.

21.

Harley

. Influence of medication choice and comorbid diabetes: the cost of bipolar disorder in a privately insured US population. Soc Psychiatry Psychiatr Epidemiol 2007; 42: 690–697.

22.

Freeman

Ruggles

. The fasting blood sugar in schizophrenia. Am J Med Sci 1933; 186: 621–630.

23.

Marshall

. Disturbances of glucose tolerance and of the acid-base equilibrium in manic-depressive insanity. Br J Psychiatry 1939; 85: 222–244.

24.

Tsai

S-Y

. A retrospective analysis of risk and protective factors for natural death in bipolar disorder. J Clin Psychiatry 2005; 66: 1586–1591.

25.

Brown

. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010; 196: 116–121.

26.

Drexhage

. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother 2010; 10: 59–76.

27.

Leboyer

. Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord 2012; 141: 1–10.

28.

Taylor

. Beyond pharmacotherapy: understanding the links between obesity and chronic mental illness. Can J Psychiatry 2012; 57: 5–12.

29.

Blixen

. Training peer educators to promote self-management skills in people with serious mental illness (SMI) and diabetes (DM) in a primary health care setting. Prim Health Care Res Dev 2014; 16: 1–11.

30.

Blixen

Perzynski

Sajatovic

Dawson

. Treating severe mental illnesses and comorbid medical conditions in the primary care setting: An idea whose time has come. Cutting Edge Psychiatry in Practice 2011; 1: 106–110.

31.

Sajatovic

. Best practices: optimizing care for people with serious mental illness and comorbid diabetes. Psychiatr Serv 2011; 62: 1001–1003.

32.

Sheehan

. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59: 22–33.

33.

Chaudhry

Jin

Meltzer

. Use of a self-report-generated Charlson Comorbidity Index for predicting mortality. Med Care 2005; 43: 607–615.

34.

Cerimele

Katon

. Associations between health risk behaviors and symptoms of schizophrenia and bipolar disorder: a systematic review. Gen Hosp Psychiatry 2013; 35: 16–22.

35.

Lysaker

Salyers

. Anxiety symptoms in schizophrenia spectrum disorders: associations with social function, positive and negative symptoms, hope and trauma history. Acta Psychiatr Scand 2007; 116: 290–298.

36.

Mueser

. Trauma, PTSD, and the course of severe mental illness: an interactive model. Schizophr Res 2002; 53: 123–143.

37.

Pokos

Castle

. Prevalence of comorbid anxiety disorders in schizophrenia spectrum disorders: a literature review. Curr Psychiatry Rev 2006; 2: 285–307.

38.

Grigsby

. Prevalence of anxiety in adults with diabetes: a systematic review. J Psychosom Res 2002; 53: 1053–1060.

39.

Collins

Corcoran

Perry

. Anxiety and depression symptoms in patients with diabetes. Diabet Med 2009; 26: 153–161.

40.

Pouwer

. Should we screen for emotional distress in type 2 diabetes mellitus? Nat Rev Endocrinol 2009; 5: 665–671.

41.

Lloyd

Dyer

Barnett

. Prevalence of symptoms of depression and anxiety in a diabetes clinic population. Diabet Med 2000; 17: 198–202.

42.

Gore

. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 2005; 30: 374–385.

43.

Gore

. Burden of illness in painful diabetic peripheral neuropathy: the patients’ perspectives. J Pain 2006; 7: 892–900.

44.

Boschert S. Use of CNS Medication May Reduce Cognition. Clinical Psychiatry News, 1 March 2008, p.39.

45.

Boschert S. Metabolic Risks of Atypicals Dissected. Clinical Psychiatry News, 1 April 2005, p.21.

46.

Miller

Massie

. Depression and anxiety. Cancer J 2006; 12: 388–397.

47.

Paschalides

. The associations of anxiety, depression and personal illness representations with glycaemic control and health-related quality of life in patients with type 2 diabetes mellitus. J Psychosom Res 2004; 57: 557–564.

48.

Trento

. Depression, anxiety, cognitive impairment and their correlations with clinical and demographic variables in people with type 2 diabetes: a 4-year prospective study. Diabetologia 2013; 56: S464–S464.

49.

Zinbarg

. The DSM-IV field trial for mixed anxiety-depression. Am J Psychiatry 1994; 151: 1153–1162.

50.

Kalra

Balhara

YPS

. Psychological assessment and management in diabetes. J Pak Med Assoc 2013; 63: 1555–1557.

51.

Balhara

YPS

Sagar

. Correlates of anxiety and depression among patients with type 2 diabetes mellitus. Indian J Endocrinol Metab 2011; 15(Suppl 1): S50.

52.

Trento

. A cross-sectional survey of depression, anxiety, and cognitive function in patients with type 2 diabetes. Acta Diabetol 2012; 49: 199–203.

53.

Mykletun

. Levels of anxiety and depression as predictors of mortality: the HUNT study. Br J Psychiatry 2009; 195: 118–125.

54.

Chwastiak

Rosenheck

Leslie

. Impact of medical comorbidity on the quality of schizophrenia pharmacotherapy in a national VA sample. Med Care 2006; 44: 55–61.